Top Markets
Coin of the day
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

4581
Pozycja w akcjach #3839
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Cena akcji
$55.98
Ostatnia synchronizacja: 2024-04-08
Kapitalizacja rynkowa
$4.59B
Zmiana (1 dzień)
-1.20%
Zmiana (1 rok)
0.00%
Kraj
JP
Handel Taisho Pharmaceutical Holdings Co., Ltd. (4581)

Kategoria

Cena 4581 z kapitalizacją rynkową B
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
4581
$55.98
Kapitalizacja rynkowa Taisho Pharmaceutical Holdings Co., Ltd.(4581)
Kapitalizacja rynkowa: $4.59B
Na dzień August 2026 spółka Taisho Pharmaceutical Holdings Co., Ltd. ma kapitalizację rynkową wynoszącą $4.59B. Według naszych danych, czyni to Taisho Pharmaceutical Holdings Co., Ltd. 3839th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej Taisho Pharmaceutical Holdings Co., Ltd. od 2011 do 2026
4581 w porównaniu do 5 najpopularniejszych stocks
Cena za 4581 Aktywa B Kapitalizacja rynkowa B Wyniki
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$62,860.00 $4.59B
$5.152T +112,191.92%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$55,351.35 $4.59B
$4.537T +98,778.61%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$50,856.25 $4.59B
$4.169T +90,748.65%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$44,436.43 $4.59B
$3.642T +79,280.41%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$34,217.20 $4.59B
$2.805T +61,024.96%